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”Det finns saker, som man måste vara fackman för att inte förstå.” 
Hjalmar Söderberg 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To my family and those who are not - and yet are close to me and my ideas. 
 
To all children with IBD. 
ABSTRACT 
The incidence rates of childhood-onset inflammatory bowel disease (IBD) have increased 
worldwide during recent decades. The changing incidence rates of paediatric IBD 
underscore the importance of early environmental exposures in the pathogenesis of the 
disease. It is possible that atypical bowel colonisation early in life creates less stable 
homeostasis between the host immune system and microbiota and thus might increase 
risk of CD later in life.  Some recent studies have reported that the childhood-onset IBD 
phenotype is characterised by increasing intestinal involvement over time and rapid 
progression to complicated disease behaviour.  
 
The aims of this thesis were to study trends in paediatric IBD incidence, to test if markers 
of atypical or disturbed early bowel colonisation are associated with an increased risk of 
CD and to describe the prognosis of childhood-onset IBD. 
 
In paper I we conducted a follow-up study of the incidence of paediatric IBD in the 
general population-based catchment area of northern Stockholm County 2002-2007. 
Medical records of all 133 children diagnosed with IBD were scrutinised. The sex- and 
age-standardised incidence of paediatric IBD was 12.8 per 10
5
 person-years. We 
concluded that the incidence of paediatric IBD during the study period was significantly 
higher than that observed in our earlier study covering 1990-2001.  
 
In paper II we studied inpatient treatment for diagnoses associated with use of antibiotics 
and risk of CD. Patients with CD born 1973-1997 and matched controls were identified 
through Swedish population registers. Inpatient treatment for pneumonia before 5 years of 
age was associated with increased risk for CD (OR 3.54, 95% CI 1.78–7.04). We 
concluded that pneumonia, and thus antibiotic therapy, early in life was associated with 
subsequent CD risk and this may represent either causation or susceptibility. 
 
In paper III we studied perinatal exposures and risk of CD during childhood. Patients 
diagnosed with paediatric CD 1990-2006 and matched controls and their perinatal 
exposures were identified through Swedish population registers. Birth by caesarean 
section was associated with a modestly increased risk for paediatric CD among boys (OR 
1.25, 95% CI 1.01–1.54). We concluded that perinatal exposures associated with delivery 
mode may have a modest influence on CD risk during childhood among boys.  
 
In paper IV we described the prognosis for all 280 patients with childhood-onset IBD in 
northern Stockholm County 1990-2007 over a median follow-up time of 8.8 years. From 
patient records we demonstrated that the cohort was characterised by extensive colitis that 
was relatively stable over time and associated with a relatively low risk of complications 
and intra-abdominal surgery. In conclusion, our findings confirm that patients with 
paediatric IBD have more widespread disease, but question the proposed dynamic and 
aggressive nature of the childhood-onset IBD phenotype.  
 
This thesis adds to our knowledge about the incidence and risks for paediatric IBD and 
the prognosis of childhood-onset IBD. This information can be used as a foundation for 
discussions on future research in the field. 
Keywords: inflammatory bowel disease, ulcerative colitis, Crohn’s disease, risk factors, 
caesarean section, incidence, prognosis  
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1 FOREWORD  
From the very first day as paediatrician I started working in the field of paediatric 
gastroenterology. I have never regretted this as I find that paediatric gastroenterology 
covers most aspects of clinical medicine. The spectrum goes from intensive care of the 
newborn child with intestinal failure to consultation with the adolescent suffering from 
long-lasting stomach pain – a clinical practice that demands knowledge and judgement 
on how to manage both soma and psyche. 
 
Most children with IBD do well most of the time. During recent decades, substantial 
progress has been made in the care of children with IBD. The development of protein-
based drugs and minimally invasive surgery have revolutionised the treatment of 
children with severe forms of IBD.  Nevertheless, these treatments sometimes have 
severe short- or long-term side effects and there are still forms of IBD that are resistant 
even to today’s treatments.  There is thus an urgent need for better treatments that could 
allow all children burdened by IBD to have a symptom-free childhood. It is my hope 
and belief that in the close future we will have unravelled the pathogenesis of IBD and 
thus be able to offer even the most chronically ill children treatments that make life 
easier. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stockholm, February 2014 
 
Petter Malmborg 
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2 LIST OF ABBREVIATIONS 
 
anti-TNF  
5-ASA  
CD 
CI  
anti tumour necrosis factor 
5-aminosalicylic acid  
Crohn’s disease 
Confidence interval 
DM1 
IBD 
Diabetes Mellitus type 1 
Inflammatory bowel disease 
IBDU Inflammatory bowel disease unclassified 
IM  
OR 
UC  
Immunomodulators 
Odds ratio 
Ulcerative colitis 
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3 INTRODUCTION 
The aetiology of inflammatory bowel disease (IBD) is still not clear. Genetic studies 
have demonstrated associations between IBD and genes that are involved in the 
immune system’s recognition and handling of intestinal microbiota. The human large 
bowel and caecum are colonised at birth by microbiota (mostly bacteria and fungi) that 
help the host extract energy from carbohydrates that cannot be digested in the small 
bowel. The immune system’s default reaction towards the microbiota is aggressive 
defence and inflammation. This primitive reaction needs to be balanced by anti-
inflammatory mechanisms so that homeostasis between host and microbiota develops 
and is maintained. IBD is thought to be explained by a loss of the, during early life 
developed, tolerance to intestinal microbiota. The incidence of IBD (and other immune 
mediated inflammatory diseases) has increased dramatically during the last century. 
Living conditions and material circumstances in most countries worldwide have 
changed fundamentally following the industrial revolution. It is possible that the IBD 
epidemic is caused by a modern lifestyle that has rapidly altered our finely-tuned 
relationship (that has evolved over millions of years) with the microbiota we host.  
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4 BACKGROUND 
4.1 HISTORICAL REMARKS 
The name ulcerative colitis (UC) to describe a condition of chronic intestinal 
inflammation was already in use during the late 19th century (1, 2).  Although several 
case reports (3-5) had been published describing chronic inflammation of the ileum, it 
was not until 1932, when Crohn, Ginzburg and Oppenheimer presented their case series 
on 14 patients with “regional enteritis”, that the disease entity gained general 
recognition (6). The name of the disease entity was later abandoned in favour of the 
eponym “Crohn’s disease” (CD) as by this time it had become obvious that the 
inflammation seen in “regional enteritis” did not have to involve the terminal ileum and 
could afflict any part of the gastrointestinal tract (7, 8). 
 
 
4.2 DEFINITIONS AND DIAGNOSIS 
CD and UC are characterised by chronic intestinal inflammation with specific but 
sometimes overlapping clinical, macroscopic and microscopic characteristics. In some 
ways CD and UC could be considered as the two extremes of a spectrum of chronic gut 
inflammation. As the two diseases share risk factors, frequently present with the same 
symptoms and signs and respond to the same treatments, they are often referred to 
under the common name inflammatory bowel disease (IBD).  
 
There are as yet no internationally accepted criteria for the diagnosis of CD or UC. The 
current expert view is that the diagnoses should be established  on the basis of non-
strictly defined combinations of clinical presentation, macroscopic appearance 
(endoscopy and radiology) and microscopic findings with the caveat that differential 
diagnoses – including infections – should be excluded (9-15).  
 
It is recommended that an IBD-colitis that cannot be classified as either CD or UC 
should be labelled inflammatory bowel disease unclassified (IBDU) until further 
discriminatory information can be obtained. If there is still no convincing evidence, 
even after thorough histopathological examination of the bowel after colectomy, use of 
the term indeterminate colitis (IC) is recommended (11).  
 
The Porto criteria from 2005 are consensus recommendations from the European 
Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) on 
examinations for the diagnosis of paediatric IBD (15). These state that all children with 
suspected IBD should be examined with both gastro-duodenoscopy and 
ileocolonoscopy and that all children with suspected CD or IBDU also should be 
examined with imaging of the small bowel. 
 
IBD is characterised by a chronically relapsing and remitting inflammation of the 
gastrointestinal tract. Patients with CD are typically burdened by a segmental and 
transmural intestinal inflammation that can involve all parts of the gastrointestinal tract. 
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In UC the intestinal inflammation is continuous and primarily superficial and restricted 
to the rectum and a variable extent of the colon in continuity. 
 
Patients with UC are almost always troubled by bloody diarrhoea, abdominal cramps 
and urgency of defecation. Symptoms of CD vary depending on the location of the 
intestinal inflammation. CD patients with colonic involvement most often present with 
diarrhoea that may be bloody.  Inflammation restricted to the distal ileum can produce 
only mild abdominal pains but may at the same time cause significant growth 
retardation and delayed puberty onset in children and adolescents (16).  In some 
patients with CD, the major symptoms can be caused by perianal disease (fistulas, 
fissures and abscesses). Concomitant systemic symptoms such as fever and weight loss 
are much more common among patients with CD than with UC. Both diseases are 
sometimes accompanied by extra-intestinal manifestations involving joints, skin, liver 
and eyes. 
 
In UC, microscopical examination often reveals pronounced distortions of crypt 
architecture that are accompanied by congested capillaries, goblet cell depletion and 
basal plasmocytosis as specific histopathological inflammatory characteristics. The 
inflammatory reaction in CD is characterised by discontinuous focal or patchy 
transmural inflammation, with epitheloid granulomas, that can induce fissuring and 
produce fibrosis. 
 
All the characteristics of UC can also be caused by CD (although microscopic 
inflammation limited to the mucosa is very rarely seen in CD). Conversely, several CD 
manifestations exclude UC as a possible differential diagnosis. This explains why most 
follow-up studies report that a significant proportion of patients with UC (or IBDU) 
will ultimately be re-classified as having CD (17, 18). 
 
Clinical, endoscopic and microscopic features helpful in distinguishing UC from CD 
are presented in Table 1, 2 and 3. 
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Table 1  
 
Clinical features distinguishing UC from CD 
 
Typical for UC 
Bloody diarrhoea 
Abdominal cramps  
Urgency of defecation 
 
Less common (and suggestive of CD), but compatible with UC 
Weight loss* 
Growth retardation** 
Delayed puberty** 
 
Incompatible with UC (and definite for CD) 
Non-bloody diarrhoea 
 
 * Only seen in patients with severe gastrointestinal symptoms of UC. 
** Only seen in children with long standing severe gastrointestinal symptoms of UC. 
Modified from (9, 19) 
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Table 2  
 
Endoscopic features distinguishing UC from CD 
 
Typical for UC 
Diffuse and continuous inflammation beginning in rectum and extending proximally 
to a variable extent; features of inflammation may include the following: 
 Granularity   
 Loss of vascular pattern 
 Friability 
 Small superficial ulcers in a background of diffuse inflammation 
 Mucopurulent exudates 
 Line of demarcation–an abrupt transition between abnormal and normal colonic  
mucosa 
 
Less common (and suggestive of CD), but compatible with UC 
Erythemateous inflammation of terminal ileum* 
Erythemateous inflammation in gastric or duodenal mucosa 
Perianal fissures 
Oral ulcers 
 
Incompatible with UC (and definite for CD) 
Discontinuous intestinal inflammation** 
Ulceration in terminal ileum 
Ulceration in gastric or duodenal mucosa 
Linear ulceration 
Cobble stoning 
Strictures 
Fistulas 
 
 * Compatible with UC only when in conjunction with an active pancolitis (backwash 
ileitis) 
** A relative macroscopic inflammatory rectal sparing can be seen in children with 
UC. A peri-appendiceal inflammation can be seen in patients with distal UC.  
 
Modified from (9-11, 15, 19, 20). 
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Table 3  
 
Microscopic features distinguishing UC from CD 
 
Typical for UC 
Chronic or chronic active colitis beginning in rectum and extending proximally to a 
variable extent; features of inflammation may include the following: 
 Goblet cell depletion 
 Distal Paneth cell metaplasia 
 Basal lymphoplasmacytosis 
 Crypt architectural distortion 
 
Less common (and suggestive of CD), but compatible with UC 
Microscopic ileitis without granuloma 
Microscopic duodeno-gastritis without granuloma 
Relative rectal sparing (histological inflammation less severe in rectum)* 
Patchiness (varying intensity of colonic inflammation)* 
Transmural inflammation (in severe attacks of UC) 
 
Incompatible with UC (and definite for CD) 
True (non-pericrypt) granulomas 
Transmural lymphoid aggregates 
Fissuring ulceration 
 
* Microscopic relative rectal sparing and patchy colitis are more often seen in children 
with new-onset UC but can also be seen in adult patients with UC due to treatment. 
Modified from (9-11, 15, 19, 20). 
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4.3 CLASSIFICATION  
Inflammatory bowel diseases (IBD) are disorders of multifactorial cause that can 
present in many different ways and the disease burden throughout life can vary 
considerably from one patient to another.  
 
The observed associations of certain early disease characteristics with a more severe 
disease course have influenced the creation and development of IBD classification 
systems. The subdivision of IBD patients in these phenotypes allows for more specific 
risk assessment that can be used to guide the choice and timing of medical and surgical 
treatment for the individual patient. The creation of international IBD classification 
systems has also enabled more valid comparisons of disease characteristics over time 
and between regions and populations. This has facilitated the quest for genetic traits 
and environmental exposures associated with certain subtypes of IBD. 
 
The most important classification when trying to predict the disease course in an IBD 
patient is still the categorisation into CD or UC. Although there is a huge span in 
disease burden within both entities there are distinct group differences in prognosis 
between patients with CD and UC. The majority of UC patients can expect to face a 
quiescent disease course with little impact on life prospects (21, 22). However, with the 
diagnosis comes a risk of an acute bout of severe colitis that might demand a life-
saving colectomy and an increased hazard of developing colorectal cancer (23). Thanks  
to modern treatment and follow-up strategies, patients diagnosed with UC in developed 
countries now seem to have an expected life-span equal to that of the general 
population (24). Patients diagnosed with CD can also expect to spend more time in 
remission than burdened by symptoms during the first decade after diagnosis (25, 26). 
Nonetheless, the potential of the intestinal inflammation in CD to produce fibrosis and 
fistulas explains why the majority of patients with this diagnosis eventually seem to 
require surgical treatment (27). Moreover, children diagnosed with CD (in contrast with 
children with UC) also face a substantial risk of growth retardation and delayed 
pubertal onset (16). It is thus not surprising that comparative studies have demonstrated 
that CD patients in general have lower self-reported quality of life than UC patients 
(28). Most contemporary studies still report a shorter life expectancy among CD 
patients, which primarily seems to be explained by progressive intestinal complications 
in a minority of patients (29, 30). Some recent studies have not been able to 
demonstrate that patients with CD have a mortality rate that differs significantly from 
the general population (31, 32). 
 
The first paper to demonstrate that certain initial disease characteristics of CD have 
bearing on the future disease course was published in 1975 by Farmer et al, and 
provided evidence of the influence of anatomical disease location on prognosis (33).  
This landmark study was the foundation for the first international CD classification 
system, which was formed in Rome in 1988 (34). It was agreed that the anatomic 
location (33) and the clinical behaviour (35) were important predictive variables to 
include in the classification of CD patients . The Rome classification was revised and 
simplified in Vienna 1998 (36) when age at onset of disease (< 40 or ≥40 years at 
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diagnosis) was added (37). The classification of Montreal in 2005 modified the Vienna 
CD classification by also recognising childhood onset IBD as a separate category (< 17 
years at diagnosis) (38). The Montreal classification moreover acknowledged that 
perianal disease should be classified separately from internal fistulising behaviour (39) 
and allowed upper gastrointestinal disease location to coexist with more distal disease. 
The Montreal consensus also for the first time applied a classification of UC, based on 
the extension of colonic inflammation and the severity at presentation or relapse, as 
studies had demonstrated that these characteristics are associated with risk of 
colectomy and colorectal cancer (22, 23). 
 
The Paris classification (Table 4) from 2010 is a paediatric modification of the 
Montreal classification (40). As an adaption to paediatric practice, the presence or 
absence of growth failure during childhood was added as a discriminatory phenotype 
characteristic. A sub-division of childhood-onset IBD was proposed according to 
diagnosis before or after 10 years of age (41). The Paris classification also introduced a 
division of upper gastrointestinal disease in jejunal versus oesophago-gastro-duodenal 
disease (42). Subdivision of extensive colitis was also suggested to specify whether the 
inflammation extended proximal to the right colonic flexure. The possibility of both 
stenosing and penetrating disease behaviour co-existing in a patient created an option to 
sub-group patients (43).  
 
Although already mentioned in the Vienna classification, the Paris classification 
stresses that the phenotyping should be based on the maximum disease 
location/extension ever observed and that the demarcation of the disease territory 
should be guided by observed inflammation at endoscopy or imaging and not by 
microscopic involvement. 
 
There have been attempts to reclassify IBD based on genetic, serological or 
immunological findings rather than clinical characteristics (44). However, these more 
modern classifications have not yet been proven to be superior to the old ones in 
predicting disease course (45).  
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Table 4  
Paris phenotype classification of childhood-onset IBD 
Age    
 A1a <10 years 
 A1b 10-<17 years 
 A2 17-<40 years 
Growth retardation   
 G0 No growth retardation 
 G1 Growth retardation 
Ulcerative colitis   
Extension E1  Ulcerative proctitis 
 E2   Left sided UC (distal to splenic flexure) 
 E3   Extensive UC (distal to hepatic flexure) 
 E4   Pancolitis (proximal to hepatic flexure) 
Crohn’s disease    
Location L1   Distal ileum ± limited caecal disease 
 L2   Colonic disease 
 L3   Ileocolonic disease 
 L4a*   Upper GI disease, proximal to ligament of Treitz 
 L4b*   Upper GI disease, distal to ligament of Treitz and 
proximal to distal ileum 
Behaviour B1   Non-stricturing, non-penetrating disease 
 B2   Stricturing disease 
 B3   Penetrating disease 
 B2B3  Both stricturing and penetrating disease 
 P**  Perianal disease 
 *L4a and L4b are modifiers that can be added to L1–L3 when concomitant upper 
gastrointestinal disease is present 
 
**P is added to B1–B3 when concomitant perianal disease is present. 
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4.4 AETIOLOGY 
The cause of  IBD is yet not clear although available evidence supports the hypothesis 
that IBD results from a loss of the during early life developed immunological tolerance 
towards the intestinal microbiota and that this loss is a consequence of environmental 
exposures (as yet largely unidentified) among genetically susceptible individuals. 
 
This hypothesis is constructed from data that to a large extent have been gleaned from 
epidemiological association studies. 
 
4.4.1 Associations with infectious agents 
The macro- and microscopic findings in CD resemble intestinal mycobacterial 
infections (46) and similarities in the presentation of UC and bacterial colitis (47) have 
spurred researchers to try to find infectious agents that could explain both diseases. 
Over the years many candidates – both bacterial (48, 49) and viral – (50, 51)  have been 
associated with IBD. However, causal relationships have not been confirmed in 
treatment studies (52) and repeated histopathological and microbiological studies have 
for most agents failed to reproduce associations. 
 
4.4.2 Associations with genes and family histories   
Twin studies have stressed the importance of both genetic and environmental factors in 
the development of both UC and CD (53, 54). It might be assumed that the genetic 
influence on the pathogenesis is greater for patients that develop IBD during childhood, 
as they have been confronted with fewer exposures during their short life span. Studies 
on children that have developed IBD during infancy have also demonstrated that 
mutations in genes involved in the IL-10 signalling system seem to be the cause for the 
intestinal inflammation in rare cases (55). 
   
The genome-wide association technique has revolutionised the possibility of finding 
links between phenotype and genotype.  Somewhat more than 100 genes have  now 
been shown to be significantly more common among IBD patients than in the general 
population (56). Approximately one-third of these loci confer susceptibility to both CD 
and UC (which is congruent with earlier studies that have demonstrated increased risk 
for CD among relatives to patients with UC and vice versa). The protein products of 
some of these genes have furthered our understanding of IBD pathogenesis. Some of 
the genes associated with CD translate to proteins that are involved in the innate 
immune system’s microbial recognition (57) and autophagy (58). UC patients more 
often carries risk genes that are translated into proteins that are involved in the barrier 
function of the intestinal mucosal (59).  
 
4.4.3 Associations with geography and period 
There are considerable differences in the incidence of IBD across different geographic 
regions and over time (60). There is almost always a strong relationship between the 
occurrence of UC and CD. Populations with a high incidence of UC also have a high 
incidence of CD and vice versa (60). The highest incidence rates of IBD have been 
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observed in Western Europe and North America where studies exploring temporal 
trends indicate that these rates are still increasing (61-63). Several recent studies have 
demonstrated that the incidence of IBD is also increasing in former low-incidence 
regions such as Asia (64). Thus IBD seems to be an emerging global disease (60). Most 
incidence studies in adult populations show higher incidence of UC than CD (60). A 
consistent historical temporal pattern of a rising incidence of UC, followed by an 
increase in CD incidence approximately 15 to 20 years later, have been observed in 
high IBD incidence regions (65-68).  
 
Rising incidence rates of childhood-onset IBD have also been observed worldwide (in 
both high and low income countries) during the last two decades (69). IBD can have its 
onset at all ages but the incidence peak is in young adulthood. It has been suggested 
that the increase in incidence of paediatric IBD could be explained by a trend towards 
the disease debuting at a younger age. A nationwide study from Switzerland that 
analysed IBD incidence in all ages found, on the contrary, a trend for disease onset 
occurring at an older age today as compared with recent decades (70). The increasing 
incidence of paediatric IBD in most countries seems to be due to a rising incidence of 
CD. The highest incidence rates of childhood-onset IBD have been observed in the 
Scandinavian countries and Canada (63, 71-73).  A steep increase in paediatric IBD 
incidence and a shift in presentation from UC to CD was observed in northern 
Stockholm County in 1990-2001 (71).  
 
4.4.4 Associations with ethnicity and socioeconomic position 
A consistent finding in early observational studies was the association between high 
socioeconomic position and increased risks for both UC and CD (74-76). Although 
significant associations with socioeconomic position have been reproduced even in 
recent studies from high incidence areas (77), most studies have failed to demonstrate 
such an association (78, 79), indicating that modern living conditions might have 
reduced differences in certain environmental exposures that were formerly associated 
with socioeconomic position.  
 
Several studies have demonstrated that different ethnic groups living in the same region 
may have significantly different IBD incidence rates (80). Whether this is explained by 
differences in genetic susceptibility or by differences in environmental exposures 
associated with ethnicity has been a source for debate. Second-generation immigrants 
to Great Britain, from Asian countries with low IBD incidence, seem to have a higher 
risk for IBD than both their parents and the indigenous European population (81); this 
indicates that environmental factors, not genetics, are the major driving force in 
changes of disease risk, at least in high incidence regions. 
 
4.4.5 Association with early environmental exposures 
The increasing incidence of paediatric IBD indicates that early environmental 
exposures are involved in the aetiology of the diseases. Known risk factors for adult-
onset CD such as smoking (82) and use of oral hormonal contraceptive (83) would be 
expected to have little or no influence on the incidence of childhood-onset IBD. 
Perinatal (84) and childhood infections (85) have been associated with risk of IBD later 
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in life, but the global inverse relation between infant mortality (which is most often 
caused by infections) and IBD incidence argues against early infections as an important 
cause for the present epidemic of paediatric IBD. The protective effect of breast feeding 
has been demonstrated in several studies (86) but sheds no light on the enigma of rising 
childhood-onset IBD incidence, as breast feeding has increased in high incidence 
regions like Scandinavia during the last decades (87).  
 
The hypothesis that the increasing incidence of immune mediated diseases in 
industrialised countries comes from altered relationships with the microbiota in early 
life (88, 89) has provided a new framework for interpretation of how early life 
exposures may influence future IBD risk. In this context, exposures that change or 
disturb the colonisation of the bowel after birth might create a less stable homeostasis 
between immune system and bowel flora and thus increase risk for later IBD. This 
hypothesis gains some credence from a study of siblings and IBD that found an 
association between having a younger sibling and a reduced CD risk, consistent with 
repeated re-colonisation of the bowel with an infantile flora from the younger sibling, 
stimulating appropriate immune system maturation in the elder sibling (90). 
 
4.5 PATHOGENESIS 
4.5.1 Early bacterial colonisation and the intestinal immune system 
Mammalian young are normally confronted with appreciable numbers of microbiota for 
the very first time when passing through the birth canal during delivery. In humans, and 
other mammalian species that harbour large amounts of bacteria in the lower 
gastrointestinal tract, the normal colonisation of the bowel thus starts with faecal 
microbes from the mother. From an evolutionary perspective the importance of the 
caecal- and colonic microbiota comes from their capacity to produce energy-rich short 
chain fatty acids from saccharides (fibre) in the diet, which the host is unable to digest 
in the small intestine (91).  The commensal microbiota thus improves the host’s 
extraction of energy from the diet and also protects the host from pathogenic strains by 
competition for substrate and space (91). To allow this interplay, an evolutionary 
adaption of the host immune system must have taken place, allowing development of 
tolerance between commensal microbiota and host but yet maintaining an aggressive 
response to pathogenic microorganisms (92, 93). 
 
The gastrointestinal tract is the primary site of interaction between the host immune 
system and microorganisms. Invading microorganisms are detected by the mucosal 
innate immune system, which responds with activation of inflammatory responses (94). 
If the host is to develop tolerance to the microbiota, the primitive non-selective 
inflammatory response of the innate immune system has to be balanced by down-
regulation of the adaptive immune system. 
 
The pathogenesis of IBD involves an inappropriate immunological response to bowel 
microbiota. This has been demonstrated in studies showing that colonic inflammation 
in patients with CD heals when a diverting ileo-stoma is constructed but recurs after re-
anastomosis and re-establishment of the faecal stream (95). Genetic studies have 
widened our understanding of this inappropriate response by showing that failure of the 
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innate immune system to identify and handle luminal bacteria is associated with an 
increased risk for IBD (57, 58). It is believed that impaired control of the microbiota by 
the innate immune system may result in a compensatory but less balanced response 
from the adaptive immune system (96). In this model, certain environmental exposures 
might trigger dysfunctional immune responses in genetically susceptible individuals, 
responses that involve an inappropriate reaction to the commensal microbiota and thus 
cause chronic intestinal inflammation. 
 
After birth, microbial colonisation of the bowel in the healthy child is dependent on 
hygiene and feeding practices (91) and the maturation of bowel flora diversity is 
influenced by the intestinal immune response of the host (93, 97). Significant 
differences in the composition of bowel flora have been demonstrated between  
Swedish infants born by the end of the 20th century and in preceding decades (98).  
Comparisons between children raised in an industrialised lifestyle in Europe and 
children living in rural Burkina Faso in West Africa have demonstrated profoundly 
greater gut microbial diversity and lower quantities of potentially pathogenic strains in 
the latter group (91).  
 
While the immune system shapes the microbiota, it is also true that certain bacterial 
strains seem to have the capacity to modulate mucosal and systemic immune function 
of the host (99). However, there seems to be a rather narrow time window for 
establishing persistent bacterial colonisation of the bowel, as demonstrated in studies 
showing that organisms introduced during infancy may establish chronic persistence, 
whereas the same organisms are promptly cleared if first encountered later during 
childhood (100, 101). Consistent with this, it has been demonstrated that mode of 
delivery and early antibiotic treatment have an impact on the composition of the 
intestinal microbiota many years after the exposure (102, 103). Atypical or disturbed 
early colonisation of the bowel might thus hinder the establishment of appropriate 
microorganisms, required for normal development of homeostasis between microbiota 
and immune system, and may allow pathogens to persist. Abnormal microbial 
colonisation  of the gut in early life might thus have implications for the risk of 
developing immune mediated diseases in general and IBD specifically later in life (93).  
 
4.6 TREATMENT, PROGNOSIS AND PREDICTION 
5-aminosalicylic acid (5-ASA) compounds were the first drugs that could be 
demonstrated to have an effect on the symptoms caused by IBD (104, 105). The 
introduction of corticosteroids during the 1950s provided potent anti-inflammatory 
drugs that radically reduced mortality owing to acute colitis in patients with UC (106). 
The experience that most patients who were saved from colectomy by corticosteroids 
during an attack of severe colitis nevertheless eventually required surgery (107) and 
that most patients with CD, despite pharmacological treatment, developed 
complications (strictures and fistulas) (27) led to the somewhat defeatist conclusion that 
medical treatments were probably unable to alter the natural disease course. The 
introduction of immunomodulators (IM) during the 1990s and inhibitors of tumour 
necrosis factor (anti-TNF) during first decade of the new millennium have evoked 
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hopes that modern treatments might have the potential to prevent development of 
disease complications in CD (108).  
 
Population-based follow-up studies have shown that most patients with UC have a mild 
disease course with relatively little influence on everyday life (22). However, within the 
first decade after diagnosis, almost all patients with UC seem to be confronted with a 
relapse of symptomatic disease and roughly one-fourth of the patients will need a 
colectomy (22, 109). The surgery rate for UC patients seems not to have changed after 
the widespread introduction of immunosuppressive drugs (109). Colorectal cancer rates 
have decreased significantly over time, and a recent study from Denmark  reported that 
a diagnosis of UC (or CD) no longer seems to significantly increase patients’ risk of 
colorectal cancer (110). Prognostic studies of adult patients with CD have concluded 
that most patients at any given time during the first decade after diagnosis are fully 
capable of working (26). Nevertheless, data from referral centres (that tend to 
overestimate risks) indicate that a high proportion of patients with CD will in time 
develop stricturing or perforating complications that demand surgical treatment (27). 
There are conflicting results about whether the surgery rates have decreased among CD 
patients during the era of immunosuppressive therapy (109, 111). 
 
Clinical experience suggests that there are several differences between childhood- and 
adult-onset IBD patients (112). Patients that have acquired UC during childhood seem 
to have a significantly higher risk of developing colorectal cancer later in life (23). 
Comparisons of phenotype characteristics at presentation and during short term follow-
up suggest that childhood-onset IBD is characterised by more extensive intestinal 
involvement at diagnosis and rapid progression to extended disease and complicated 
disease behaviour (61, 113, 114). There are only a few population-based studies that 
more specifically describe the long term prognosis of patients with childhood-onset 
IBD (115-118). The reported substantial risks for corticosteroid dependency and 
surgery in some of these studies (116, 117) have lent further support to the hypothesis 
that childhood-onset IBD represents a more severe phenotype.   
 
As paediatric IBD treatment also includes promotion of normal growth, aggressive 
therapy is sometimes advocated in children, even in the absence of gastrointestinal 
symptoms (119). The intensity of treatment for adult patients with IBD has been guided 
by the actual symptom burden and has aimed at establishing clinical remission (120).  
This paradigm has now been questioned in CD where (in contrast with patients with 
UC (121)) there is a weak relationship between intestinal mucosal inflammation and 
symptoms measured as disease activity indices (122). It has been suggested that the 
medical treatment should rather aim at promoting mucosal healing as this outcome has 
been associated with reduced subsequent disease activity and decreased need for active 
treatment  (123, 124). Given the risks associated with immunosuppressive therapy, 
early intensive therapy or treatment of symptom-free patients can only be justified in 
those who are at high risk of a severe or disabling disease course. Clinical, biochemical, 
serological and genetic markers that are associated with a more severe disease course in 
patients with IBD have been identified but their individual and combined accuracy to 
predict disease course have yet been low  (125, 126). 
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5 AIMS 
 
5.1 GENERAL AIMS 
The general aims of this thesis were to increase knowledge of the aetiology and 
prognosis of childhood-onset IBD. 
 
5.2 SPECIFIC AIMS 
5.2.1 Paper I 
To describe the occurrence of paediatric IBD in northern Stockholm County during 
2002-2007 as an extension of the previous study on the incidence of childhood onset 
IBD in northern Stockholm County covering 1990-2001.  
 
5.2.2 Paper II 
To test the hypothesis that antibiotic exposure during infancy and early childhood 
disrupts the homeostasis between host immune system and intestinal microbiota and 
thus increases the risk for CD later in life. 
 
5.2.3 Paper III 
To test the hypothesis that atypical microbial bowel colonisation, resulting from birth 
by caesarean section, leads to the development of a less stable homeostasis between 
host immune system and intestinal microbiota and thus increases the risk of CD during 
childhood.   
 
5.2.4 Paper IV 
To describe the prognosis in a population-based cohort of patients that have developed 
IBD during childhood.  
To find predictors of a severe disease course in childhood-onset IBD and thus identify 
early in the disease course patients who may benefit from more intensive medical 
treatment. 
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6 MATERIALS AND METHODS 
 
6.1 STUDY SUBJECTS AND METHODS 
6.1.1 Paper I  
All patients aged 0-15 years with paediatric IBD, diagnosed 2002-2007 and living in 
northern Stockholm County at time of diagnosis, were identified. Patients were 
identified by searching the records of patients at Astrid Lindgren Children’s Hospital 
(which is the only paediatric gastroenterology unit in northern Stockholm County), the 
paediatric gastroenterology units in southern Stockholm County and in bordering 
counties, as well as all adult gastroenterology departments within the catchment area.  
 
Patients were diagnosed according to the criteria that were used in earlier incidence 
studies in Stockholm and Sweden (71, 127-129): 
 
To be given a diagnosis of IBD, the patient had to have a history of more than six 
weeks of diarrhoea, abdominal pain, weight loss, retarded growth or fever and an 
intestinal infection had to be ruled out by bacterial and parasitological tests.  
 
1. A diagnosis of UC required:  
 Endoscopic findings of continuous mucosal inflammation involving the 
rectum and extending for variable distances in a proximal direction.  
 Histopathology in intestinal biopsies consistent with UC.   
 
2. A diagnosis of CD required at least two of the following three criteria:  
 Endoscopic or radiographic findings of intestinal inflammation 
characterised by discontinuous intensity, ulcerations, cobblestoning or 
strictures. 
 Histopathology in intestinal biopsies consistent with CD. 
 Perinal or intestinal fistulas or abscesses. 
 
3. A diagnosis of IBD unclassified (IBDU) was recorded if endoscopic, histological 
or radiographic evidence was compatible with inflammatory bowel disease but 
did not fulfil the criteria of UC or CD. 
 
After revision, 133 children fulfilled the diagnostic criteria for IBD. Patients in the 
cohort were followed for a median of 5.8 years (range 1.0-8.9 years). If the initial IBD 
diagnosis changed during follow-up, the final diagnosis was used for calculations of 
incidence. 
 
Data on the population in the catchment area (188 437 individuals <16 years of age 
lived in northern Stockholm County in 2005) during the study period were obtained 
from Statistics Sweden and the City of Stockholm.  
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6.1.2 Paper II  
In the Swedish Inpatient Register we identified 1098 patients with CD born during the 
period 1973 to 1997.  Each case was matched with up to six controls identified through 
the Swedish Medical Birth Register. Controls were selected at random among children 
born in the same delivery unit, in the same year and of the same sex. The matched 
sample and analysis was used to limit substantial confounding by temporal, geographic 
and social factors. 
 
Seven common diagnoses that usually require antibiotic treatment were chosen as 
proxy markers of significant antibiotic exposure. Inpatient treatment for these 
diagnoses between birth and age five years for cases and controls was identified 
through the Swedish Inpatient Register. 
 
The Swedish National Patient Register was started in the 1964 when the National 
Board of Health and Welfare started to collect information regarding inpatients at 
public hospitals. Initially the register only covered six counties in Sweden but over the 
next two decades the register expanded gradually. In 1984 the Ministry of Health and 
Welfare decided that participation was mandatory for all 21 counties in Sweden. From 
1987 the National Patient Register thus includes information on all inpatient admissions 
to hospital and provides information on diagnoses and procedures for each stay. The 
quality of the inpatient register is checked regularly and it is estimated that over the last 
decade less than one percent of the records have been incomplete (130). Validation 
studies have shown that 85-95% of the diagnoses are accurately logged in the register 
(130). The use of the personal identity number (a ten-digit number maintained by the 
National Tax Board) given to all citizens in Sweden in the National Patient Register 
allows individual linkage to information contained in other national registers (131). 
 
6.1.3 Paper III  
Through the Swedish Inpatient Register, we identified 1536 patients diagnosed with 
paediatric (<16 years) CD between 1990 and 2006. Each case was matched with ten 
controls identified through the Medical Birth Register.  
 
Information on birth mode and other markers of perinatal exposures, including 
maternal diagnoses during pregnancy, was provided by the Medical Birth Register. 
Information on neonatal infectious exposures for the child was provided by the 
Inpatient Register. Parental socioeconomic index was provided by the national Census 
that occurred nearest in time to the delivery.  
 
The Swedish Medical Birth Register was founded in 1973 and includes data on almost 
all deliveries in Sweden. It is compulsory for every health care provider to report to the 
register and the information available is collected from medical records from prenatal, 
obstetric and neonatal care. Even though the basic structure of the register has remained 
unchanged, there have been some major modifications to content and methods of data 
collection over the years. For the main part of our study period it was possible to get 
full information from the Medical Birth Register on maternal diagnoses before and 
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during pregnancy and at delivery, maternal smoking during pregnancy, mode of 
delivery, birth weight and gestational age of the child and neonatal diagnoses. 
 
6.1.4 Paper IV  
Patient files for all the 280 patients diagnosed with paediatric IBD in the general 
population-based catchment area of northern Stockholm 1990-2007 were scrutinised 
from diagnosis until 2011. For patients diagnosed after 1997 most files were 
computerised and accessible using Stockholm County’s patient file system. For patients 
diagnosed before 1997 the files had to be requested from the Stockholm County’s 
patient file archives. For those patients who were referred to departments outside 
Stockholm during the follow-up period, copies of patient files were requested. 
 
Of the 280 patients with IBD, 249 could be followed throughout the study period from 
diagnosis to 2011. In total, patients within the cohort were followed for 2727 person-
years, giving a median follow-up time of 8.8 years (range 1.0-20.8 years). Due to loss 
to follow-up, 103 person-years could not be examined, corresponding to a loss of 3.7% 
of the maximum possible follow-up time. 
 
By the end of the study period, all patients (100%) had been examined with 
colonoscopy (including visualization of the caecum). Of the 200 CD patients, 190 
(95%) had been examined with ileoscopy, 188 (94%) with gastroscopy and 183 (92%) 
with small bowel imaging by the end of follow-up. 
 
Patients were phenotyped within the framework of the Paris classification (40) (Table 
4). 
 
Disabling symptoms were defined according to the criteria used in a study from the 
Saint-Antoine Hospital, Paris (126). The follow-up period for each patient was divided 
into five-year periods, with an assessment of disease burden in each of these periods. 
Patients were considered to have disabling symptoms if they had significant symptoms 
of diarrhoea, abdominal pain, fever, fatigue or EIM for more than one fifth of the time 
in each five-year period. Patients that underwent a colectomy or had a permanent stoma 
were defined as having continuous disabling symptoms. 
 
For each five-year period after diagnosis, patients were classified as corticosteroid-
dependent if they were prescribed more than two steroid courses or required more than 
three months continuous treatment (126).  
 
Medication at 5, 10 and 15 years after diagnosis was categorised according to the step-
up model (Figure 1). 
 
Disease activity as shown by routine follow-up endoscopy at one year was defined by 
the endoscopist as mucosal healing or persistent erosive mucosal inflammation. 
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The step-up treatment model  
Anti-TNF 
IM 
5-ASA 
 
A complicated disease course in patients with CD was defined as progression to 
extended location or complicated behaviour or need for intra-abdominal surgery during 
follow-up. 
 
Figure 1  
Maintenance therapy categorised according to the step-up model in which 5-ASA 
represents step one, IM (azathioprin, mercaptopurin and methotrexate) step two and 
anti-TNF (infliximab and adalimumab) step three. 
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6.2 STATISTICAL ANALYSIS 
6.2.1 Paper I  
Yearly incidence rates were standardized to the Swedish population in 2002 by sex and 
age. Confidence intervals for incidence rates were calculated assuming a Poisson 
distribution. Trends in incidence rates were calculated using a Poisson regression 
model.  
 
6.2.2 Paper II  
Conditional logistic regression was used to analyse associations of inpatient treatment 
for diagnoses associated with antibiotic exposure, with risk for CD. The association of 
each diagnosis with CD risk was tested in univariate analysis. Where statistically 
significant associations were observed these diagnoses were included in a multivariate 
logistic regression analysis. In the final model the association of inpatient treatment for 
pneumonia with CD risk was also adjusted for markers of exposure that in former 
studies have been associated with CD risk and so may constitute potential confounding 
factors. 
 
6.2.3 Paper III  
Conditional logistic regression was used to analyze associations of caesarean 
section with paediatric CD risk. The analysis was adjusted for established risk 
factors for CD and for exposures during pregnancy and after delivery in the 
study that were associated with an increased risk for paediatric CD.  
 
6.2.4 Paper IV 
The cumulative proportion of patients that progressed to complicated disease behaviour 
or underwent intra-abdominal surgery or immunosuppressive therapy was estimated by 
the Kaplan-Meier method. Differences in survival between those diagnosed in the early 
or in the late part of the study period were assessed using the Log rank test. 
 
Cox proportionate hazard regression was used to analyze the association of patient 
characteristics at diagnosis and during early follow-up with a complicated disease 
course. The association of early patient characteristics with a complicated disease 
course was tested in univariate and multivariate analyses. 
 
In an additional analysis not included in the paper, the performance of the selected 
variables in the Cox model to predict requirement for intra-abdominal surgery between 
two and ten years after diagnosis was tested using logistic regression. The sensitivity, 
specificity, positive and negative predictive values of these measures were calculated.  
 
6.2.5 Overall 
In all papers (I-IV) normally distributed continuous variables are presented as mean and 
standard deviation. Measures with a skewed continuous distribution are presented as 
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median and range. Categorical variables are presented as proportions and compared 
using the chi-square test or Fishers exact test for small sample sizes.  
In all papers the statistical significance level was set at p < 0.05.  
 
Analyses in paper I and IV used SPSS.  Analyses in paper II-III used the SAS software 
package. 
 
6.3 ETHICS 
Approval for the studies reported in all papers was obtained from the Regional Ethical 
Review Board at Karolinska Institutet, Stockholm. 
 
For paper I;   Dnr 04-915/1, Dnr 2009/1435-31/3 
For paper II;  Dnr 2005/1232-31, Dnr 2011/1352 32 
For paper III;  Dnr 2005/1232-31, Dnr 2006/1043-32, Dnr 2008/314-32 
For paper IV;  Dnr 20011/120-31, Dnr 2012/1125-32 
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7 RESULTS 
 
7.1 PAPER I  
During the study period (2002-2007), 133 patients were diagnosed with paediatric IBD 
(96 (72%) with CD, 29 (22%) with UC and 8 (6%) with IBDU) in northern Stockholm 
County.  
 
The standardised incidence (per 105 person-years) of IBD was 12.8 (95% confidence 
interval (CI) 10.8-15.2), 9.2 (95% CI 7.5-11.2) for CD and 2.8 (95% CI 1.9-4.0) for 
UC.  
 
An increasing incidence rate of UC (58.4% (CI 22.8%-104.3%, p<0.01)) was observed 
during the study period. No statistically significant temporal trend was observed for the 
incidence of IBD (3.2% (95% CI -6.6%-14.0%, p=0.54)) or CD (-8.8% (95% CI -
18.6%-3.0%, p=0.14)) during the study period. 
 
A statistically significant male predominance was observed for CD (sex ratio 1.5 (95% 
CI 1.0-2.3, p<0.05)).  
 
The incidence rate of IBD in northern Stockholm County during this study period 
(2002-2007) was significantly higher than during the previous six-year period 1996-
2001 (4.8% (95% CI 0.3%-9.5%, p<0.05)). When the entire study period of 1990-2007 
was analysed, we found significant temporal trends for increasing incidence rates of 
overall IBD (6.6% (95% CI 4.1%-9.2%, p<0.01)) and CD (7.7% (95% CI 4.7%-10.8%, 
p<0.01)). No significant temporal trend in incidence rate of UC (3.3% (95% CI -1.4%-
8.1%, p=0.17)) could be detected for the entire study period of 1990-2007.  
(See Figure 1, paper III, page 33) 
 
 
7.2 PAPER II  
Inpatient treatment for pneumonia before five years of age was the only diagnosis that 
was significantly associated with subsequent CD. Inpatient treatment for otitis media 
was positively associated with CD although the association did not reach statistical 
significance. 
 
When pneumonia and otitis media were included in the same conditional regression 
model, the association of otitis media with CD was attenuated, while the association of 
pneumonia with CD remained significant.   
 
The adjusted associations (adjusted also for maternal age) of inpatient treatment for 
pneumonia between birth and age five years were significant with both childhood- 
onset CD (odds ratio (OR) 2.74, 95% CI 1.04-7.21) and adult-onset CD (OR 4.94, 95% 
CI 1.83-13.23). 
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7.3 PAPER III  
 
7.3.1 Overall caesarean section 
Birth by ccaesarean section was not associated with an increased risk of paediatric CD. 
However, examination of males and females separately revealed a modestly increased 
risk for paediatric CD among boys delivered by caesarean section. The association of 
caesarean section with paediatric CD among boys was statistically significant even 
after adjustment (adjusted for maternal IBD, maternal age, number of older siblings and 
gestational age) (OR 1.25, 95% CI 1.01-1.54). 
 
7.3.2 Elective caesarean section 
In infants born at term after 1981 we could analyse the association of caesarean section, 
divided into elective and acute, with paediatric CD. In this subset elective caesarean 
section was associated with a statistically significant raised risk of paediatric CD. 
Maternal urinary tract infection was found to be significantly associated with risk for 
paediatric CD in this subset and was therefore introduced as a potential confounder. 
Adjustment for potential confounding factors, including maternal urinary tract 
infection, did not eliminate the statistical significance of the association (OR 1.36, 95% 
CI 1.02-1.80). 
 
7.4 PAPER IV  
 
7.4.1 Childhood-onset IBD 
During the study period (1990-2007) 280 patients were diagnosed with childhood-onset 
IBD (200 (71%) with CD, 74 (26%) with UC and 6 (2%) with IBDU) in northern 
Stockholm County. 
 
The proportion of IBD patients that were classified as having disabling symptoms 
decreased significantly over time (1-5 years: 32% and 11-15 years: 15%, p<0.01). 
(See Figure 1, paper IV, page 22) 
 
The proportion of IBD patients that did not use any prescribed medication significantly 
increased over time (at 5 years: 6% and at 15 years: 28%, p<0.01).  
(See Figure 2, paper IV, page 23) 
 
The proportion of IBD patients that were classified as corticosteroid dependent 
significantly decreased over time (1-5 years: 31% and 11-15 years: 14%, p<0.01). 
 
7.4.2 Childhood-onset UC 
Pancolitis (E4) was the most common disease presentation in patients with UC. 
 
  
  27 
 
Extended intestinal inflammation during follow-up was observed in 6 (22%) of the 27 
UC patients that did not present with pancolitis (E4).  
(See Figure 3, paper IV, page 24) 
 
The cumulative risk for colectomy in patients with UC, five and ten years after 
diagnosis, was 6% (95% CI 2%-12%) and 8% (95% CI 4%-20%) respectively.   
 
7.4.3 Childhood-onset CD 
In patients with CD, isolated colonic disease (L2) was the most common disease 
location. Twenty-nine patients (14%) with CD disease had a complicated disease 
behaviour at diagnosis (10 (5%) presented with intestinal complications (B2, B3) and 
19 (10%) with perianal fistulas or deep fissures (+P)).  
 
Extended disease location over time was observed in 29 (15%) of the 189 CD patients 
that did not present with pan-enteric disease (L3+L4). By the end of follow-up, pan-
enteric disease had been observed in 21 (11%) of the 200 CD patients.  
(See Figure 4, paper IV, page 24) 
 
Among the 190 CD patients that presented with non-stricturing, non-penetrating 
intestinal inflammation, 25 (13%) developed complicated disease behaviour during 
follow-up. (See Figure 5, paper IV, page 25) 
By the end of the study period perianal fistulas had formed in 17 (9%) of the 181 CD 
patients that were not afflicted with perianal disease at diagnosis. 
 
The cumulative risk for intra-abdominal surgery in patients with CD five and ten years 
after diagnosis was 13% (95% CI 8%-18%) and 22% (95% CI 15%-28%) respectively. 
 
In the multivariate Cox proportionate hazard regression analysis, persistent erosive 
mucosal inflammation at one year re-endoscopy was the only characteristic that was 
significantly associated with an increased risk (hazard ratio 14.56 (95% CI 1,79–
118,68) of a complicated disease course (defined as progression to extended location or 
complicated behaviour or need for intra-abdominal surgery) two years after diagnosis. 
(Figure 2) 
 
In the sensitivity and specificity analysis, we tested the predictive performance of the 
only selected variable in the multivariate Cox regression model. More specifically, we 
tested the ability of persistent erosive mucosal inflammation at one year re-endoscopy 
to predict progression to a complicated disease course in a subset of 87 patients that 
presented with uncomplicated disease and who were re-endoscoped between six 
months and two years after diagnosis and had more than five years of follow-up. 
Persistent mucosal inflammation at one year re-endoscopy had a sensitivity of 95%, a 
specificity of 56%, a positive predictive value of 60% and a negative predictive value 
of 97% for a complicated disease course between two and ten years after diagnosis 
within the sub-cohort.   
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Figure 2 shows a Kaplan-Meier curve on the progression rate to a complicated disease 
course two years after diagnosis by mucosal healing at one year re-endoscopy for 
patients (n=106) presenting with an uncomplicated childhood-onset CD in northern 
Stockholm 1990-2007. 
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8 DISCUSSION 
 
8.1 STRENGHTS 
The strengths of this thesis include that we present data on incidence (paper I) and 
prognosis (paper IV) of childhood-onset IBD from a relatively large cohort based on 
the general population, with patient information collected continuously over 18 years, 
and that nearly all the patients could be followed, giving a median follow-up time of 
almost 10 years after diagnosis. 
 
Another major strength of this thesis is that we could use the prospectively collected 
data in Swedish national population registers and thus identify a large number of 
patients with childhood-onset CD. This allowed us to study the possibly weak (but 
from an aetiological perspective important) associations of early life exposures with 
risk of CD and adjust the analysis for several important potentially confounding factors 
(paper II and III). 
 
8.2 WEAKNESSES 
The major weakness of the two regional general population-based cohort studies in this 
thesis (paper I and IV) is the relatively small number of patients; this limits the 
possibility of detecting small changes in incidence over time and confirming observed 
differences in disease presentation and prognosis. 
 
The major weakness of the two national register studies in this thesis is that we could 
only adjust for factors that were collected in the national registries; thus the associations 
we demonstrated might have been confounded by unreported yet important exposures 
such as diet, smoking and drug exposure (paper II and III).  
 
8.3 INCIDENCE 
The observed increasing incidence of paediatric IBD and the predominance of CD in 
northern Stockholm County in this thesis (paper I) are consistent with global trends. 
During recent decades increasing incidence rates of both childhood-onset UC and 
childhood-onset  CD have been reported in epidemiological studies from most 
continents (69). However, it is worth noting that the increase in the incidence of IBD 
had stagnated and that the incidence of CD had even decreased at the end of the study 
period. The plateauing incidence of paediatric IBD in our study contrasts with most 
contemporary incidence reports. Future studies will establish whether we have 
observed a permanent shift from low to stable high incidence rates, a transition pattern 
that was observed in adult-onset IBD incidence studies from North America and 
Western Europe during the 1950s-1970s (65).  
 
Increasing incidence of immune mediated diseases (including allergic and autoimmune 
diseases and IBD) has been observed in Europe and North America during the last 
decades. Although the rise in some of these diseases might be attributed to an increased 
awareness and improved diagnostic procedures, it is worth noting that the incidence of 
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childhood-onset Diabetes Mellitus type 1 (DM1) has increased dramatically in 
Scandinavia during recent decades (132, 133). DM1 has a rather precise definition and 
is fatal when untreated, so it is implausible that the increase in incidence could be 
explained by changes in diagnostic procedures or improved awareness of the disease. In 
northern Stockholm the increase in paediatric IBD incidence at the end of the 1990s 
was paralleled by a steep increase in childhood-onset DM1 incidence (71, 134). It 
should also be noted that the faecal calprotectin test as a screening tool for children 
with long-standing gastrointestinal problems was introduced in northern Stockholm 
after the transition to high incidence rates of paediatric IBD. It thus seems more 
plausible that the observed increase in childhood-onset IBD rates is real and reflects a 
less stable gastrointestinal immunological balance in at least some children born during 
the last three decades. 
 
The higher incidence rate of CD than UC observed in our study is consistent with most 
epidemiological studies on paediatric IBD from the last decade. However, an inverse 
distribution of the two diseases was recently reported from the Uppsala region, just 
north of Stockholm, in a contemporary childhood-onset IBD cohort (63, 135). Striking 
differences in CD/UC ratio between geographically, socioeconomically and genetically 
comparable countries have also been reported, implying that these might rather reflect 
differences in classification than true discrepancies. Misclassification could be expected 
to be more common within childhood-onset IBD, as colitis is the most common disease 
presentation in children with CD and thus makes differentiation from UC more 
complicated. The creation of more specific common diagnostic criteria for paediatric 
IBD would allow international comparisons to be made with greater certainty (136). 
 
Reported incidence rates of paediatric IBD from the Scandinavian countries are among 
the highest in the world. However, the rates seem to differ significantly between the 
neighbouring countries (72, 137, 138). The differences in IBD incidence could hardly 
be explained by differences in health care provision or general awareness of IBD, as all 
the Scandinavian countries have similar health care organisation and share a long-
standing interest in IBD incidence studies. This finding should prompt further 
comparative studies in search of environmental factors that have changed recently and 
could explain the ongoing global, but by country borders varying, epidemic of 
paediatric IBD (65). 
 
8.4 PNEUMONIA AND CAESAREAN SECTION  
In papers II and III in this thesis we made use of Swedish national population registers 
to conduct hypothesis testing case-control studies. We demonstrated that inpatient 
treatment for pneumonia during early childhood and birth by elective caesarean section 
were associated with significantly increased risks for CD. These findings lend some 
support to the hypothesis that atypical first or early disrupted microbial colonisation of 
the bowel might hamper the development of stable homeostasis between immune 
system and bowel flora and thus increase the risk of CD later in life in susceptible 
individuals.  
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In paper II we used inpatient treatment as a proxy marker of significant antibiotic 
treatment as by that time no Swedish register for drug prescription was available for 
studies such as ours. As most antibiotic treatments for children are prescribed in 
outpatient settings (139) the extent of the difference in true exposure to antibiotics 
between cases and controls might be questioned. Recently published studies from 
Denmark and Finland that have used nationwide databases of antibiotic purchases have 
confirmed the association of antibiotic prescription during early childhood with an 
increased risk for CD later in childhood (140) (141). The association of early 
prescription of antibiotics with risk of CD in adulthood (where we found the strongest 
association) was not studied in these papers. As the influence of genetic traits could be 
expected to be stronger for patients that develop CD early in life it is possible that 
adult- rather than childhood-onset CD is of even greater interest when evaluating the 
influence of early environmental exposures. Although the association of early antibiotic 
use with CD risk seems consistent it should be emphasised that the association might be 
explained by immune dysregulation causing increased susceptibility to both early 
bacterial infections and later CD in some individuals. However, the absence of an 
association of inpatient treatment for pneumonia after five years of age with CD risk 
later in life in makes this explanation less plausible. 
 
By using national registers in paper III we identified a large number of patients and 
thus were able to examine a possibly low-magnitude, but aetiologically interesting, 
association, such as birth mode, with CD risk. By focusing on patients with childhood-
onset CD we were able to adjust for some potentially important confounding maternal 
factors (such as urinary tract infections and smoking during pregnancy) that had been 
added more recently to the National Medical Birth register. Another reason why we 
restricted the analysis to childhood-onset disease is that children have not yet been 
exposed to environmental factors to the same degree as adults, so the association of 
birth mode with paediatric CD is less likely to be confounded by unmeasured exposures 
such as smoking. We demonstrated that birth by elective caesarean section was 
associated with a significantly increased risk for CD. The association of overall 
caesarean section with increased risk of CD among males (who constitute the main 
proportion of paediatric CD patients) gave further strength to our interpretation that 
birth mode may influence CD risk during childhood. Our conclusion is also supported 
by a recent national cohort study from Denmark that found that individuals born by 
caesarean section were at a modest but significantly increased risk of developing IBD, 
both CD and UC, during childhood (142). However, the Danish findings do somewhat 
question our interpretation as the authors found a more pronounced risk among children 
delivered by acute caesarean section. These findings suggest that the increased risk for 
IBD seen among children delivered by caesarean section might not be explained by an 
atypical first bacterial colonisation, but by the factors that prompted non-elective 
caesarean section. Breast feeding has been reported to be less common among infants 
delivered by caesarean section (143) seems to reduce the risk of IBD (86). Neither of 
these two national register studies allowed adjustment for early feeding pattern and it is 
possible that early breast feeding might be a causal factor. Although the apparently 
consistent association of birth mode with paediatric CD is of aetiological interest, the 
association is too modest to suggest that advice on delivery procedures should be 
altered. Although the proportion of children that are delivered by caesarean section has 
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increased more than threefold during the last decades in Sweden (144) this change in 
delivery practice may at the most (assuming a causal association) explain risk in a very 
small fraction of the  100 or so children (135, 145) who are now diagnosed annually 
with CD in the Sweden.  
 
 
It could be speculated that the increase in prescription of antibiotics to children in 
Sweden, which lasted until the mid-1990s (139) could have contributed to the 
increasing incidence rates of childhood-onset CD during the past two decades (63, 71, 
128, 129, 135, 145).  If this is true one would expect to see a decline in paediatric CD 
incidence rate in the next decade, as the prescription of antibiotics to children 0-4 years 
of age fell by 37% between 1995 and 2004 in Sweden (139). Results from a 
comparative European study covering 1994-1997 argue against early use of antibiotics 
being of major importance for the epidemic of childhood-onset CD in Scandinavia, as 
prescription of antibiotics in a country such as Spain, with low incidence of paediatric 
CD (146) was estimated to be almost twice as high as in Sweden (147).  
 
8.5 PRESENTATION AND PROGNOSIS  
In paper IV we confirmed that the childhood-onset IBD phenotype, compared to the 
adult-onset phenotype, seems to be characterised by more extensive disease at 
diagnosis. However, the predominance of isolated colonic disease observed in our CD 
cohort conflicts with reports from most other contemporary paediatric IBD cohorts 
(114, 116, 148). These suggest a paediatric CD phenotype characterised by even more 
widespread intestinal inflammation, often involving the large and small bowel as well 
as the upper gastrointestinal tract (pan-enteric disease). The significantly different 
disease distribution observed in our cohort might reflect real differences. However, the 
distinct difference in dominating phenotype – a difference seen even between the 
Scandinavian countries (148) – rather suggests differences in classification. This 
speculative explanation emphasises the  importance of implementing the recently 
created Paris paediatric IBD classification (40) as a common platform for upcoming 
paediatric studies.   
 
The large majority of the patients in this relatively large population-based childhood-
onset IBD cohort could be followed until the end of the study period. Follow-up over a 
median of almost ten years did not lend any support to the hypothesis that childhood-
onset IBD represents a particularly dynamic and aggressive IBD phenotype (114, 116, 
117, 149). The complication and intra-abdominal surgery rates were significantly lower 
in our cohort than those observed in earlier studies of population-based childhood-onset 
IBD cohorts (116, 117, 150, 151). The patients in our cohort had, compared with 
contemporary adult-onset IBD cohorts, similar stability of disease location over time 
and comparable or somewhat lower complication and surgery rates (21, 25, 152). Our 
findings are consistent with recently published comparative studies from Hungary and 
Canada that could not find differences in progression to complicated disease behaviour 
or requirement for surgery between childhood- and adult-onset CD cohorts (150, 153). 
Prospective studies that compare presentation and progression of IBD between cohorts 
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of children and adults with a common standardized diagnostic and follow-up protocol 
would be of great interest to further explore the differences in phenotype by age.   
 
The observed relatively mild and decreasing disease burden in our cohort over time 
implies that the natural disease course in childhood-onset IBD might be less aggressive 
than previously believed. This finding is major importance as the focus of IBD 
treatment is now shifting from symptom control to prevention of irreparable intestinal 
damage (154). This treatment strategy has attracted great interest among paediatric 
gastroenterologists, as childhood-onset IBD has long been considered a more 
aggressive phenotype and as paediatric patients have to face a lifetime accompanied by 
disease. The ongoing era of biologics has raised hopes that modern immunosuppressive 
treatments should have the capacity to change the natural disease course of IBD (108). 
Most biologics have initially been tested in rheumatological diseases and then later 
moved on to trials for other inflammatory diseases such as IBD. The frontline 
experience gained in treating rheumatoid arthritis has thus served as an inspiration for 
gastroenterologists when trying to develop care for patients with IBD (154). The 
concept of treating even subclinical inflammation in rheumatoid arthritis is now well 
established, as treatment guided by biochemical inflammatory markers has been 
associated with reduced joint destruction and lower levels of functional disability (155-
157). Analogous with this concept, earlier and more intense pharmacological treatment 
to prevent structural damage to the intestine is now also advocated by some experts in 
IBD (154). Most attention has been directed to CD, where there is a weaker association 
between symptoms and intestinal inflammation (122) and  complications (strictures and 
fistulas) requiring intra-abdominal surgery seem to develop in almost all patients over 
time (27). To alter the natural disease course of CD it is suggested that treatment 
choices should be guided not only by symptoms but also by more objective markers of 
intestinal inflammation (158). Intestinal mucosal healing has repeatedly (as 
demonstrated in our cohort) been associated with a low risk of developing intestinal 
complications in prognostic studies (123, 159). Some experts thus recommend that 
treatment of CD should aim to achieve and maintain both clinical remission and 
mucosal healing (a combination for which the term deep mucosal healing is proposed) 
(160). A randomised controlled trial (REACT-2) was started in 2013 investigating 
whether an accelerated step-up treatment guided by deep remission leads to fewer 
complications as compared with the classical symptom-guided step-up approach. In this 
first trial aimed at modifying the course of  CD, the recently developed intestinal 
damage scores will be used as endpoints, in addition to complication and surgery rates 
(161). This and hopefully other forthcoming trials will provide evidence of the capacity 
of IM and anti-TNF to prevent structural damage to the intestine and thus their potential 
to modify the natural disease course in IBD.  
 
The concept of treating beyond symptom control might be less controversial in 
paediatric CD, where impaired growth is already used as a marker of significant 
inflammatory activity that prompts more active treatment, even in the absence of overt 
gastrointestinal symptoms. However, if one looks to the rheumatology experience for 
guidance, it should be kept in mind that treatment concepts designed for joint 
inflammation probably have to be adapted to suit the gastrointestinal tract. Even if 
immunosuppressive therapy turns out to have the potential to prevent intestinal fibrosis, 
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this might not be a concern from the patients’ perspective. Intestinal damage may not 
necessarily cause a functional disability in the way a destroyed joint will (162). As 
demonstrated in our study, several of the patients with CD who had significant fibrotic 
tissue transformation (strictures) also had relatively mild symptoms during the 
following years and did not require intra-abdominal surgery. Future modifying studies 
of IBD should thus ideally also include the newly developed functional disability index 
for IBD patients as endpoint (163). When comparing with current treatment concepts in 
rheumatology it should also be noticed that disease-modifying treatment in this disease 
does not seem to be associated with an increased risk for development of lymphoma 
(164). On the contrary immunosuppressive treatment in CD entails a modest but yet 
increased risk for development of fatal lymphoma in young males with IBD (165). 
Given the risks associated with immunosuppression in IBD, early intensive therapy 
could only be justified in those patients who face a high risk of a complicated disease 
course. The risk that a patient with rheumatoid arthritis will develop a disabling disease 
course can to some extent be predicted at diagnosis by presence of auto-antibodies, 
levels of biochemical inflammatory markers and joint erosion scores (166). In contrast 
prognostic studies in CD have so far demonstrated low performance of combined early 
clinical, endoscopic, biochemical, serological and genetic markers to predict a 
complicated disease course (125, 167). The relatively mild disease course of the 
patients in our cohorts suggests that a substantial proportion of childhood-onset CD 
patients might not need disease modifying treatment and that aiming for symptomatic 
alleviation in these patients might be sufficient. For the time being, the initiation of 
treatment aiming beyond symptomatic control might only be justified in paediatric CD 
patients that present with early significant intestinal (or perianal) damage (deep 
ulcerations or stricturing or fissuring disease behaviour (25, 116, 151, 168)). The 
stronger association of non mucosal healing than persistent symptoms with 
development of a complicated disease course in our study suggests that maintenance 
treatment intensity in this high risk group should be guided by disease activity 
assessments by endoscopy. 
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9 CONCLUSIONS 
 
 The incidence of paediatric IBD in northern Stockholm 2001-2007 was higher 
than the rates observed 1990-2001. The previous rapid increase in CD incidence 
seems though to have levelled out. The incidence rate of paediatric IBD in 
northern Stockholm was consistently higher than those reported from most other 
regions in the world. 
 
 The association between CD and both birth by elective caesarean section and 
inpatient treatment for pneumonia prior to the age of five years gives some 
credence to the theory that atypical or disrupted bowel colonisation during early 
childhood might increase the risk for CD later in life. 
 
 Patients with childhood-onset IBD were characterised by extensive colitis that 
was relatively stable over time and associated with a relatively low risk of 
complications and intra-abdominal surgery. Our findings confirm the more 
extensive disease location in paediatric IBD but question the proposed dynamic 
and aggressive nature of the childhood-onset IBD phenotype that has been 
indicated previously. 
 
 The strong association of mucosal healing at one year with an uncomplicated 
disease course suggests that endoscopy should be used to guide treatment 
intensity in childhood-onset CD.  
 
 
  
36 
 
10 CHALLENGES 
Although knowledge concerning paediatric IBD is rapidly growing much research is 
yet to be done.  
 
The global epidemic of childhood-onset IBD seem to be explained by changing 
environmental exposures associated with the modern lifestyle that is now enjoyed by 
most people in high and middle income countries. The observed increase in IBD 
incidence in Stockholm does not seem to be explained by increasing use of either 
antibiotics or caesarean section. However the association of these exposures with CD 
risk suggests that an atypical (from an evolutionary perspective) pattern of bowel 
colonisation early in life might alter the susceptibility to disease later life in some 
individuals.  
 
The recent mapping of the full human microbiome has gained much attention and 
fuelled interest in the intricate symbiosis or commensalism between host and 
microbiota and its implications for human health (169). Future research ought to 
explore further the role of the bowel microbiota in the pathogenesis of IBD; to 
characterise the pattern of bowel flora before disease onset in those who later in life 
develop IBD (170); to examine whether modification of the bowel flora with pre- or 
probiotics might have an impact on disease activity in already afflicted patients (171); 
to study whether transplantation of faecal matter from a healthy donor is a way of 
correcting the imbalance the between immune system and the bowel microbiota in 
patients with IBD (172); to study if there is an association between IBD and modern 
agriculture’s increasing use of biocides that are potentially harmful to bowel flora 
(173).   
 
The incidence trends in paediatric IBD should be studied consistently in high, middle 
and low income countries. Assuming that antibiotic treatment and birth mode (and 
other factors associated with these, possibly with a greater effect on bowel colonisation) 
have some impact on IBD incidence, one might expect a steep increase in paediatric 
IBD incidence rates, during the next decades, in the rapidly developing low and middle 
income countries of Eastern Asia, where most children now seem to have a high 
exposure to antibiotics and the rate of caesarean section is increasing (174, 175).  
The concept of treating of paediatric IBD with immunosuppression has been questioned 
as onset of IBD in early childhood seems to be associated with defective anti-
inflammatory responses in some patients (55). Nevertheless this concept could be the 
ruling paradigm for some years to come as several studies have proven that 
immunosuppressive therapy effectively relieves symptoms and promotes growth in 
paediatric IBD patients (176-179). New biologics with somewhat different modes of 
action than anti-TNF are now on the verge of being added to the pharmacological 
repertoire for the treatment of paediatric IBD (180-182). The rare but sometimes severe 
side effects of immunosuppressive therapy (165, 183) suggest that these drugs should 
be reserved for patients that have disabling symptoms or face a substantial risk of 
developing complications. Future studies ought to further study the association of 
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clinical, endoscopical, histological, radiological, biochemical, genetic, serological and 
microbial characteristics with severe disease course in order to build predictive models 
that can identify high risk groups as early as at diagnosis, groups for whom the 
advantages of immunosuppression could perhaps outweigh the risks (184). Taking the 
unique features of paediatric IBD into consideration, the performance of these models 
should also be tested in population-based cohorts of patients with childhood-onset IBD. 
Future studies should also address whether non-invasive measures of disease activity 
such as faecal calprotectin or imaging techniques could be used to guide the treatment 
intensity in IBD patients (122, 185, 186). The hypothesis that early immunosuppressive 
therapy may have the potential to prevent the transition from acute to chronic 
inflammation and thus alter disease progression to follow a more benign course should 
be elaborated further (187). 
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11 SAMMANFATTNING PÅ SVENSKA 
Crohns sjukdom (CD) orsakas av en kronisk inflammation som kan uppträda i hela 
mag-tarmkanalen. Vid CD kan tarminflammationen leda till bildning av sårgångar 
genom tarmväggen (fistlar) och förträngningar av tarmen på grund av ärromvandling 
(strikturer).  
Ulcerös kolit (UC) orsakas av en kronisk inflammation som alltid uppträder i 
ändtarmen men som även kan omfatta hela tjocktarmens slemhinna.  
CD och UC uppträder ofta med samma symptom och liknande 
inflammationsutbredning och kräver ofta likartade behandlingar varför de båda 
sjukdomarna inte sällan med ett gemensamt namn kallas för inflammatoriska 
tarmsjukdomar (IBD). 
 
Orsaken till varför IBD uppkommer är fortfarande ofullständigt känd. Studier av 
tvillingar har visat att ärftliga faktorer spelar stor roll för uppkomsten av IBD. Under de 
senaste två decennierna har antalet barn och ungdomar som insjuknar i IBD i världen 
ökat. Den ökande incidensen av IBD bland barn och ungdomar kan inte förklaras med 
förändringar i arvsanlagen utan måste förklaras med ändrad livsmiljö. IBD antas kunna 
förklaras med en förlust av den tidigt i livet förvärvade immunologiska toleransen 
gentemot tarmens bakterieflora. Allmänt förbättrade levnadsvillkor under de senaste 
decennierna har medfört att barn idag konfronteras med färre och delvis andra 
mikroorganismer än tidigare generationer. Hos barn som växer upp i rika länder 
kolonialiseras tjocktarmen efter födelsen av delvis andra bakterier än de som tidigare 
generationer anpassat sig till. Det är möjligt att denna ur ett evolutionärt perspektiv 
avvikande kolonisation skapar en mindre stabil jämvikt mellan tarmfloran och 
immunförsvaret. En sådan obalans skulle kunna leda till en ökad risk för att insjukna i 
IBD senare i livet. Flera arbeten som publicerats under de senaste åren har visat att de 
som insjuknar under barn- och ungdomsåren i IBD verkar har en sämre prognos än de 
som insjuknar i vuxen ålder. Man har därför antagit att IBD som debuterar under 
barnaåren utgör en svårare form av sjukdomen med ökad risk för komplikationer 
(strikturer och fistlar) vilka ofta kräver kirurgisk behandling. Nya undersökningar 
studier talar för att tidigt insatt behandling med immunförsvarsdämpande läkemedel har 
minskat behovet av bukoperationer. Behandling med immunförsvarsdämpande 
läkemedel kan dock öka risken för att drabbas av ovanliga men allvarliga infektioner 
och hos pojkar och unga män även lymfkörtelcancer. Behandling med 
immunförsvarsdämpande läkemedel kan därför bara försvaras hos de barn och 
ungdomar som löper en stor risk för att drabbas av ett allvarligt sjukdomsförlopp.  
 
Syftet med denna avhandling var att följa utvecklingen av incidensen av IBD bland 
barn och ungdomar, att testa om en avvikande eller tidigt störd bakteriell kolonisation 
av tarmen var kopplad till en ökad risk för att drabbas av CD senare i livet, att beskriva 
prognosen vid insjuknande i IBD under barn- och ungdomsåren och att testa om 
tarminflammationens karaktär tidigt i sjukdomsförloppet kan användas för att förutse 
vilka patienter som löper en ökad risk för att drabbas av ett mer allvarligt 
sjukdomsförlopp. 
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I artikel I genomförde vi en uppföljande studie av hur incidensen av IBD bland barn 
och ungdomar i norra Stockholms län utvecklats mellan 2002 och 2007. Efter 
journalgenomgång kunde vi konstatera att 133 barn och ungdomar insjuknat i IBD 
under tidsperioden vilket motsvarar en incidens (per 100 000 barn och år) om 12,8 
(95% konfidens intervall (CI) 10,8–15,2) för IBD, 9,2 (95% CI 7,5–11,2) för CD och 
2,8 (95% CI 1,9–4,0) för UC. Incidensen av pediatrisk IBD under tidsperioden var 
signifikant högre än i vår tidigare studie som omfattade åren 1990-2001. Under 
studieperioden noterades en statistiskt signifikant ökning av incidensen i UC. Den 
stadiga ökningen av incidensen av CD som vi observerade under den förra 
studieperioden verkade dock ha avstannat även om incidensen sett ur ett globalt 
perspektiv fortfarande var mycket hög. 
 
I artikel II studerade vi om sjukhusvård för diagnoser som kräver antibiotikabehandling 
ökade risken för att drabbas av CD senare i livet. Med hjälp av svenska 
befolkningsregister kunde vi identifiera 1 098 patienter födda mellan 1973 -1997 med 
CD och 6550 matchade kontroller. Vi kunde konstatera att sjukhusvård före fem års 
ålder (men inte senare) för lunginflammation var kopplat med en ökad risk för att 
insjukna i CD både under barn- och ungdomsåren (odds kvot (OR) 2,74, 95% CI 1,04–
7,21) och i vuxen ålder (OR 4,94, 95% KI 1,83–13,23). Slutsatsen var att 
lunginflammation, och därigenom antiobiotika-behandling, tidigt i livet var förenat med 
en ökad risk för att senare i livet drabbas av CD och att detta samband antingen 
förklaras av gemensam sårbarhet för de båda sjukdomarna eller avspeglar ett orsak-
verkans-samband. 
 
I artikel III undersökte vi om förlossningssätt påverkade risken för att insjukna i CD 
under barn- och ungdomsåren. Vi identifierade 1 536 patienter som mellan 1990 och 
2006 fått diagnosen IBD under barn och ungdomsåren och matchade dem med 15 439 
kontroller via svenska befolkningsregister. Uppgifter om omständigheterna före, under 
och efter förlossningen hittade vi i det nationella medicinska födelseregistret. 
Förlossning med kejsarsnitt var kopplat med en något ökad risk för att insjukna i CD 
under barn- och ungdomsåren för pojkar (OR 1,25, 95 % CI 1,01–1,54) men inte för 
flickor (OR 0,99, 95% CI 0,76–1,29). En något ökad risk för CD bland både flickor och 
pojkar sågs bland de som förlösts med planerat kejsarsnitt (OR 1,36, 95% CI 1,02–
1,80). Slutsatsen var att kejsarsnittsförlossning (eller andra med förlossningssättet 
sammanhängande faktorer) något ökade risken för att insjukna i CD under barn och 
ungdomsåren och då framförallt bland pojkar .  
 
I artikel IV beskrev vi prognosen för de alla de 280 patienter som insjuknade i IBD 
under barn- och ungdomsåren i norra Stockholms län mellan 1990 och 2007 under en 
medianuppföljningstid om 8,8 år med ledning av journaldata. I denna 
populationsbaserade kohort kunde vi visa att andelen patienter med IBD som upplevde 
handikappande symptom minskade statistiskt signifikant under uppföljningstiden. Vid 
insjuknandet konstaterades att flertalet av patienterna med både UC och CD hade en 
utbredd men till tjocktarmen begränsad tarminflammation. Tio år efter diagnos hade 
8% (95% CI 4%-20%) av UC patienterna behövt genomgå kolektomi (operativt 
avlägsnande av tjocktarmen) och 22% (95% CI 15%-28%) av CD patienterna hade 
blivit opererade i buken. Jämfört med andra populationsbaserade kohorter (bestående 
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av såväl patienter som insjuknat under barnaåren som i vuxen ålder) var 
inflammationsutbredningen relativt stabil över tid och relativt få patienter kom att 
utveckla komplicerad sjukdom eller krävde bukkirurgi. De patienter som vid 
endoskopisk kontroll ett år efter diagnos uppvisade en kvarstående sårig tarmslemhinna 
hade en ökad risk för att drabbas av ett komplicerat sjukdomsförlopp (hazard kvot 
14.56, 95% CI 1,79–118,68). Vår studie bekräftar att de patienter som insjuknar i IBD 
under barn- och ungdomsåren utmärks av en utbredd tarminflammation, men 
ifrågasätter hypotesen om att de som insjuknar i unga år, skulle vara drabbade av en 
mer dynamisk och aggressiv form av sjukdomen än de som insjuknar i vuxen ålder. 
Den starkare kopplingen mellan en oläkt tarmslemhinneinflammation än mellan 
betydande symptom ett år efter diagnos och ett komplicerat sjukdomsförlopp visar att 
intensiteten i underhållsbehandlingen vid CD även bör vägledas av endoskopiska fynd. 
 
Denna avhandling bidrar med betydelsefulla kunskaper om incidensen av, riskfaktorer 
för och prognosen vid IBD hos barn och ungdomar vilka bör användas som 
utgångspunkt för framtida forskningsprojekt inom området. 
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